Targeting caveolin-1: dual challenges in tumor immunity and drug therapy strategies

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Tumor immunity is vital for suppressing cancer initiation and progression.
• Tumor metabolic reprogramming and immune evasion are key factors in cancer development.
• Caveolin-1 (Cav-1) is implicated in cell signaling, lipid metabolism, and immune responses, and is often upregulated in various cancers.

Purpose of the Study:

• To review the structure and functions of Cav-1, focusing on its role in tumor-associated immune cells.
• To discuss how Cav-1-mediated lipid metabolic reprogramming impacts antitumor immunity.
• To highlight challenges in developing Cav-1-targeting drugs and its potential as a therapeutic target.

Main Methods:

• Literature review focusing on Cav-1's role in tumor immunity and metabolism.
• Analysis of Cav-1 expression patterns across different cancer subtypes.
• Synthesis of current understanding of Cav-1's mechanisms in immune evasion and therapy resistance.

Main Results:

• Cav-1 is frequently upregulated in many cancers but shows context-dependent expression, varying by cancer subtype.
• Cav-1 mediates lipid metabolic reprogramming, which can regulate antitumor immunity.
• Tumor metabolic reprogramming, influenced by Cav-1, can drive immunosuppression through cytokines like TGF-β and IL-4, leading to immune evasion.

Conclusions:

• Cav-1 is a potential biomarker and therapeutic target for cancer due to its role in tumor immunity and metabolism.
• The heterogeneous expression and context-specific functions of Cav-1 present challenges for drug development.
• Further research into Cav-1's mechanisms in tumor immunity is crucial for developing effective cancer therapies.